Previous Article | Next Article ![]()
Journal of Virology, October 2004, p. 10221-10229, Vol. 78, No. 19
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.19.10221-10229.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
*
Department of Molecular Biology, Princeton University, Princeton, New Jersey
Received 24 February 2004/ Accepted 15 April 2004
|
|
|---|
|
|
|---|
The genome of HCMV contains two unique domains, one long and one short, each flanked by repeat sequences. Two open reading frames, TRS1 and IRS1, include sequence from both repeated and unique domains. The N-terminal two-thirds of pTRS1 is encoded in the c repeat region, and the remainder of the protein is coded within the unique short region. The related protein, pIRS1, is encoded in the internal or c' repeat region plus the adjacent unique short region. Consequently, the N-terminal domains of pTRS1 and pIRS1 are nearly identical, and the two proteins have different C-terminal domains (37). Because their amino-terminal domains are encoded in the repeat region, the transcription of these genes is controlled by identical immediate-early promoters. Both pTRS1 and pIRS1 are packaged into the virion and therefore are delivered to the cell immediately upon infection (32); pTRS1 and pIRS1 can be detected in infected cells as early as 2 h postinfection (33, 36).
The first function ascribed to pTRS1 and pIRS1 was transcriptional activation. Both proteins were found to act in conjunction with the immediate-early transcriptional regulatory proteins, IE1 and IE2, but not on their own, to increase expression from the UL44 promoter in transient-transfection assays (36). Subsequent analysis identified TRS1/IRS1 as 1 of 11 loci that are required for transient complementation of HCMV oriLyt-dependent DNA replication (28). In this assay, pTRS1 and pIRS1 likely facilitate the accumulation of other proteins that function directly in the replication process (15). More recently, pTRS1 and pIRS1 have been shown to block the double-stranded RNA-dependent protein kinase R response pathway, an antiviral pathway that shuts down protein synthesis in infected cells (5). Finally, we have shown that pTRS1, but not pIRS1, acts late during the virus replication cycle to facilitate the production of virions (3).
Our analysis of pTRS1 function used a mutant virus, ADsubTRS1, that lacks the central portion of the TRS1 open reading frame (3). Although DNA replication was normal and there was no significant difference in the accumulation of six viral mRNAs in mutant compared to wild-type virus-infected fibroblasts, ADsubTRS1 produced
10-fold-reduced yields of both extracellular and intracellular virus. In addition, the localization of the pp65 and pp71 tegument proteins was found to be abnormal in mutant virus-infected cells. After infection with ADsubTRS1, these two tegument proteins localized exclusively to the nucleus and did not move to the cytoplasmic sites of virus assembly, as happens after infection with wild-type virus. Since this defect was not complemented by protein expressed from the corresponding open reading frame, IRS1, it was clear that this was a separate function from those exhibited by both proteins and, therefore, the activity was ascribed to the unique C-terminal one-third of pTRS1. Indeed, deletion of the pIRS1 coding region produces a viable virus that replicates with wild-type kinetics (3, 17).
Our earlier analysis localized the ADsubTRS1 defect to the late phase of the replication cycle. As viral DNA accumulates during the late phase of infection, structural proteins are produced, capsid shells are assembled, DNA is inserted into the shells, mature capsids associated with some tegument proteins move from the nucleus to the cytoplasm, additional tegument proteins are added, and the capsid with tegument proteins are enveloped in a virus-modified membrane to produce an infectious virion (reviewed in reference 7). Now we demonstrate that the production of DNA-filled C-capsids and nuclear reorganization induced by HCMV infection both require pTRS1 function.
|
|
|---|
Microarray analysis. At 72 h postinfection, polyadenylated RNA was isolated from cells by using the MicroPoly(A)Pure mRNA purification kit according to the manufacturer's protocol (Ambion). Cy3-dUTP-labeled cDNA was produced from 5 µg of RNA. Microarray slides were made as previously described (9). Each array contained PCR-amplified cDNA segments corresponding to the known HCMV open reading frames, as well as control cellular genes, and DNAs were printed in triplicate on amino-silane-coated glass slides. The cDNA (60 µl) was then hybridized to arrays at 42°C for 14 h (11). Arrays were washed and then scanned by using a GenePix 4000B scanner (Axon Instruments) at a 10-µm resolution. Analysis of the data was done with GenePix Pro 4.0 software (Axon). The Axon software was set to subtract both local and hybridization background values. After aberrant spots were flagged, the mean intensity of each spot was calculated, and the average values were normalized by using the cellular cDNAs. Values calculated for the cellular cDNAs were used for comparisons between slides.
Thin-section electron microscopy. Fibroblasts were infected with ADwt, ADsubTRS1, or ADsubIRS1 at a multiplicity of infection (MOI) of 0.5 PFU/cell. At 72 h postinfection cells were washed once with phosphate-buffered saline (PBS) and fixed in 3% glutaraldehyde in sodium cacodylate buffer at room temperature for 1 h. Staining was performed by resuspending the cell pellet in an aqueous solution of 1% osmium tetroxide and 2% uranyl acetate. The stained cells were dehydrated through ethanol steps and then embedded in a blend of EmBed 812, dodecyl succinic anhydride, and nadic methyl anhydride resins (Electron Microscopy Sciences). Thin sections were prepared and post-sectioning staining was performed with aqueous 2% uranyl acetate and modified Sato's lead citrate (10) before sections were viewed at 80 kV with a Leo912a electron microscope.
Sucrose gradient analysis of capsids. The basic protocol used was described previously (26), but several modification were used. Fibroblasts were infected with ADwt or ADsubTRS1 at an MOI of 0.5 PFU/cell. At 72 h postinfection the cells were washed in TNE buffer (20 mM Tris [pH 7.4], 500 mM NaCl, 1 mM EDTA) and then lysed in the same buffer with 1% Triton. Cellular membranes were disrupted by three freeze-thaw cycles, and particles in the lysate were pelleted through a 2-ml 35% sucrose cushion at 20,000 rpm in an SW41 rotor for 75 min. The pellet was resuspended in a small volume of TNE and treated with RQ1 DNase I (Promega), 8 mM dithiothreitol, and 4 mM MgCl2 to digest unencapsidated DNA. The lysates were sonicated to disperse aggregates and layered onto 20 to 65% sucrose gradients, and the gradients were spun at 40,000 rpm in an SW41 rotor for 20 min. When viewed with top illumination from a fiber optic lamp, bands corresponding to A-, B-, and C-capsids were visible. The gradient was fractionated, and a portion of each fraction was analyzed by Western blotting. After electrophoresis through a 10% sodium dodecyl sulfate (SDS)-containing gel, proteins were transferred to a Protran membrane (Schleicher & Schuell) and then blocked in 0.5% bovine serum albumin. Membranes were probed with antibodies to the major capsid protein (UL86; monoclonal antibody [MAb] 28-4) and minor capsid protein (UL85; MAb 85-13), both gifts from W. Gibson (The Johns Hopkins University School of Medicine). The secondary antibody was an 125I-conjugated goat anti-mouse immunoglobulin G (Perkin-Elmer). Membranes were exposed to a phosphor screen for accurate quantitation. A Storm PhosphorImager (Molecular Dynamics) was used for scanning; ImageQuant software was used for data analysis.
For analysis of the virion DNA content, 100-µl portions of each fraction were incubated for 2 h at 37°C in an equal volume of 2x capsid lysis buffer (200 mM NaCl, 20 mM Tris [pH 7.4], 50 mM EDTA, 1.2% SDS, 0.2 mg of proteinase K/ml). The DNA was denatured for 1 h at 65°C with one-tenth volume of 3 M NaOH and then adjusted to a final salt concentration of 6x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate). Precipitated material was removed by a 2-min centrifugation in a microfuge. The supernatant was analyzed by slot blot assay by using a probe to a 1,697-bp fragment containing the HCMV UL82 gene prepared by random priming with the Klenow fragment of DNA polymerase I in the presence of [32P]dCTP (6).
Immunofluoresence. Fibroblasts were grown to near confluence on sterile glass coverslips in six-well plates. Cells were then infected with ADwt or ADsubTRS1 at an MOI of 0.5 PFU/cell. After 72 h cells were washed in PBS, fixed for 15 min in 2% paraformaldehyde in PBS, washed again with PBS, and permeabilized for 15 min in 0.1% Triton X-100 in PBS. After a wash with PBS containing 0.2% Tween 20, the cells were incubated for 1 h in PBS-blocking buffer containing 2% bovine serum albumin and 0.2% Tween 20. Cells were then incubated in PBS-blocking buffer for 1 h at room temperature with a mouse MAb to the major capsid protein (pUL86, clone MAb 28-4, diluted 1:5 [W. Gibson, The Johns Hopkins University School of Medicine]), minor capsid protein (pUL85, clone MAb 85-13, diluted 1:5 [W. Gibson]), smallest capsid protein (pUL48.5, clone 11-2-23, diluted 1:5 [W. Britt, University of Alabama School of Medicine]), polymerase accessory protein (pUL44, diluted 1:400 [Virosys]), replication compartment protein (pUL112-113, diluted 1:5 [E. Bogner, Universität Erlangen-Nürnberg]), or the virus-coded DNase (pUL98, diluted 1:5). After a further wash with PBS containing 0.2% Tween 20, slides were incubated for 30 min at room temperature with a goat anti-mouse- or anti-rabbit-Alexa 546 conjugate (diluted 1:1,000; Molecular Probes). The secondary antibody was supplemented with 1 ng of DAPI (4',6'-diamidino-2-phenylindole; Molecular Probes)/ml to counterstain chromosomal DNA. After the final wash, the coverslips were mounted with Slow-Fade (Molecular Probes) to preserve samples on microscope slides. Microscopy and image acquisition was carried out with a Zeiss LSM510 confocal microscope.
FISH. The fluorescence in situ hybridization (FISH) technique was described previously (20). Briefly, 72 h after fibroblasts were infected with ADwt, ADsubTRS1, or ADsubIRS1 at an MOI of 0.5 PFU/cell, cells were harvested, treated with 75 mM KCl for 20 min at 37°C, and fixed in methanol-acetic acid (3:1) at 4°C. Spread chromosomes and interphase nuclei were treated with DNase-free RNase A (100 mg/ml; Sigma) in 2x SSC prior to hybridization. DNA probes were labeled with biotin-16-dUTP (Roche) by nick translation (31). The DNA fragment length was assessed to be 200 to 500 bp. The denatured probe (50 to 100 ng) was hybridized to chromosomal DNA in 50% formamide-2x SSC-10% dextran sulfate-0.1% SDS at 37°C under a sealed coverslip. After a washing step, samples were preincubated for 30 min in a blocking solution (3% blocking reagent [Roche] in 4x SSC) and then incubated for 30 min at 37°C with avidin-fluorescein isothiocyanate (Vector) diluted 1:400 in blocking solution. Samples were washed and, for amplification of the fluorescent signal, treated sequentially with avidin-specific biotinylated antibody (Vector) diluted 1:40 in 4x SSC and with avidin-fluorescein isothiocyanate diluted 1:400 in blocking solution. Chromosomal DNA was counterstained with propidium iodide, and the samples were mounted in Slow-Fade. Images were captured on a Zeiss LSM510 confocal microscope.
DNA analysis. To study cleavage of the concatemeric DNA, a protocol modified from (23) was used; fibroblasts were infected at an MOI of 0.5 PFU/cell, and total DNA was prepared. HpaI-restricted DNA fragments were electrophoretically separated on a 0.8% agarose gel and subjected to Southern blot analysis. A random-primed, 32P-labeled, 500-bp SacI-AatII fragment corresponding to the viral RL3 gene was used to probe HCMV genomic termini. This probe recognizes both the terminal repeat long (TRL) and the inverted repeat long (IRL) regions. As a control, ADwt DNA, purified from virions, was processed in the same way. Bands were quantified by using the Molecular Dynamics PhosphorImager system and ImageQuant software.
|
|
|---|
![]() View larger version (114K): [in a new window] |
FIG. 1. Microarray analysis of the ADwt (A) and ADsubTRS1 (B) mutant reveals similar patterns of HCMV gene expression in infected fibroblasts. DNA arrays were probed with cDNA prepared from fibroblasts infected at an MOI of 0.5 PFU/cell and harvested at 72 h postinfection. The top three panels in each section have cDNAs that span the entire HCMV genome along with several controls. The bottom panel in each section contains a set of control cellular genes.
|
Five late virus-coded proteins, including the major capsid protein, were assayed previously by Western blotting and found to accumulate to normal levels after infection with ADsubTRS1 (3). To determine whether the defect in ADsubTRS1-infected cells results from the failure to properly localize the proteins that comprise the capsid, we monitored the location of the major capsid protein pUL86 (Fig. 2A and B), minor capsid protein pUL85 (Fig. 2C and D), and smallest capsid protein pUL48.5 (Fig. 2E and F) by immunofluorescence. Moreover, we localized several virus-coded proteins involved in DNA replication: replication compartment protein pUL112-113 (Fig. 2G and H), polymerase accessory protein pUL44 (Fig. 2I and J), and DNase pUL98 (Fig. 2K and L). No differences were evident in the locations of the proteins at 72 h postinfection with ADwt compared to ADsubTRS1. Thus, the principal capsid constituents, as well as several proteins involved in HCMV DNA replication, are produced and accumulate in the correct cellular compartment of ADsubTRS1-infected fibroblasts.
![]() View larger version (37K): [in a new window] |
FIG.2. Immunofluorescence analysis of the intracellular localization of HCMV proteins involved in capsid formation and DNA replication after infection with ADwt (A, C, E, G, I, and K) or ADsubTRS1 (B, D, F, H, J, and L). Fibroblasts were fixed at 72 h postinfection and probed with MAbs specific to the pUL86 major capsid protein (A and B), pUL85 minor capsid protein (C and D), pUL48.5 smallest capsid protein (E and F), pUL112/113 replication compartment protein (G and H), pUL44 polymerase accessory proteins (I and J), and pUL98 virus-coded DNase (K and L). The left panel in each pair shows the antibody-specific signal alone (red), and in the right panel of each pair the DNA is counterstained with DAPI (blue). Bars, 10 µm.
|
![]() View larger version (203K): [in a new window] |
FIG. 3. The ADsubTRS1 mutant causes a decrease in capsid production and a disruption of viral replication centers. Thin-section transmission electron microscopy of fibroblasts infected at an MOI of 0.5 PFU/cell and fixed at 72 h postinfection. Fibroblasts were infected with ADwt (A and B) or ADsubTRS1 (C and D). The nuclear envelope is indicated by arrows, and the arrowheads point to capsids. NIEPs, virions, and DBs are labeled in the cytoplasm (A and C). All images (except for higher magnification insets) are taken at the same magnification. Bars, 1 µm.
|
Lysates were prepared at 72 h after infection with ADsubTRS1 or ADwt and then subjected to velocity sedimentation. Figure 4A displays a representative separation of the A-, B-, and C-capsids. All three capsid types were observed after separation of the particles in lysates of wild-type virus-infected cells and, as expected, B-capsids were the most abundant. A band comprised of C-capsids was seen after centrifugation of extracts from wild-type virus- but not mutant virus-infected cells. The numbers of C-capsids in the ADsubTRS1 mutant were too few to be visualized above the background in the gradients.
![]() ![]() View larger version (56K): [in a new window] |
FIG. 4. Rate velocity gradient separation of HCMV nucleocapsids. Lysates from ADwt- or ADsubTRS1-infected fibroblasts were layered onto 20 to 65% sucrose gradients. (A) Illumination from the top revealed three light-scattering bands in ADwt, indicated by circled letters. A-capsids are empty; B-capsids are precursors that contain the scaffolding protein, which is then released from the capsid to allow DNA insertion and the maturation to the C-capsid form. (B) Profile of gradient fractions probed for the presence of capsid proteins or HCMV DNA. This representative sample shows the distribution of both the major capsid protein (on the left axis) and viral DNA (on the right axis) along the fractions of the rate velocity gradient. (C) When the ADsubTRS1 mutant is compared to ADwt, the reduction in capsid numbers is different for the two different capsid types analyzed. Quantitation for both the B and C peaks shows the fold decrease for ADsubTRS1 compared to the ADwt strain.
|
2-fold fewer B-capsids and 10-fold fewer C-capsids than did ADwt. The decrease in the number of C-capsids in ADsubTRS1-infected cells argues that pTRS1 is required for efficient DNA encapsidation. We were not able to reliably quantify A-capsids in gradient fractions since they overlapped the major B-capsid peak. However, visual inspection of the gradients (Fig. 4A) and electron microscopy images indicated that the mutant and wild-type viruses produced similar percentages of A-capsids. Concatemeric ADsubTRS1 DNA is cleaved normally. It is generally believed that, early in the HCMV replication cycle, the viral genome circularizes and begins rolling circle replication (24), although a recent report suggested that in herpes simplex virus type 1 (HSV-1) there is little or no circular viral DNA found during a productive infection (16). Previous work in HCMV has indicated that DNA is replicated from the ori-Lyt origin and concatemers of the viral genome are generated. The concatemers must then be cleaved into unit-length pieces as the DNA is packaged into preassembled procapsids. This cleavage has been shown to utilize ATP and proceed concomitantly with insertion of the DNA into the capsid (12). In HSV-1 infections, at least seven proteins function at this point, including the large UL28 and small UL15 terminase subunits and the UL6 portal protein (18, 38, 39). In HCMV, the protein products of UL56 and UL89 have been identified as the large and small terminase subunits (4, 34), but further details of the HCMV proteins involved in this process have not been investigated.
It has previously been shown that ADsubTRS1 DNA is replicated with kinetics similar to that of ADwt (3), and we have shown here that there is a defect in the production of DNA-containing C-capsids. Consequently, it appeared possible that pTRS1 is required for cleavage of concatemeric HCMV DNA during the packaging process. To investigate whether the mutant DNA is properly cleaved, we determined the ratio of free ends (cleaved genomes) to fused ends (genomes that are still part of the concatemer) in the mutant compared to wild-type virus-infected cells (22, 23). Total DNA was isolated from fibroblasts at several times after infection and genomic termini were monitored by Southern blotting with a probe to the IRL3/TRL3 region of the long repeats (diagramed in Fig. 5A). Since the probe corresponds to the repeat region, it will identify the free end (TRL3), as well as the internal fused region (IRL3), of the HCMV genome. HpaI-digested viral DNA generates free ends of 7 kbp and two fragments (10 and 13 kbp each) that span the long-short junction; genomic isomerization yields the two different sizes of junction fragments. The ratio of free to fused ends was not significantly different in DNA isolated from ADsubTRS1-infected compared to ADwt-infected cells (Fig. 5B and Table 1). The normal accumulation of free HCMV genome ends in ADsubTRS1-infected cells indicates that pTRS1 is not required for cleavage of viral DNA concatemers.
![]() View larger version (39K): [in a new window] |
FIG. 5. Processing of newly replicated viral DNA. Fibroblasts were infected with either ADwt or ADsubTRS1 virus at an MOI of 0.5 PFU/cell, and the total DNA was prepared at the indicated times. (A) Shows the relevant fragments of an HCMV genome digested with HpaI. (B) A representative Southern blot with a 32P-labeled probe specific for RL3. Purified cell-free viral DNA was used as a control for size. The indicated fused and free fragments were quantified by using a phosphorimager.
|
|
View this table: [in a new window] |
TABLE 1. Percentage of total viral DNA that has been cleaved from the concatemer
|
To further document the nuclear reorganization defect, we monitored the location of viral DNA in infected fibroblasts by FISH. Relatively early after infection (24 h), a few fluorescent dots of DNA were observed in both ADwt-infected (Fig. 6A) and ADsubTRS1-infected (Fig. 6C) nuclei. Later after infection (96 h), the numbers and sizes of fluorescent patches had increased and coalesced in the nuclei of wild-type virus-infected cells (Fig. 6B). In contrast, the DNA-containing dots and patches did not coalesce late after infection with the mutant virus. Rather, many small dispersed fluorescent puncta accumulated (Fig. 6D). The altered pattern of DNA accumulation in ADsubTRS1-infected nuclei could be the cause or effect of a failure to assemble DNA-containing capsids. As an additional control, viral DNA accumulation was monitored in cells infected with ADsubIRS1, and the pattern of fluorescence was indistinguishable from that seen for the wild-type virus (data not shown). We conclude that, although normal levels of ADsubTRS1 DNA are produced, it is not localized normally in the nucleus.
![]() View larger version (53K): [in a new window] |
FIG. 6. FISH of fibroblasts fixed infected with ADwt (A and B) or ADsubTRS1 (C and D) and then fixed at 24 h (A and C) or 96 h postinfection (B and D). HCMV DNA was visualized by FISH analysis and appears in green. Cellular DNA is counterstained with propidium iodide and appears in red.
|
|
|
|---|
Electron microscopic examination of infected cells revealed that the TRS1-deficient virus produced reduced numbers of virus particles in comparison to its wild-type parent (Fig. 3). Fewer virions, NIEPs, and DBs were observed in the cytoplasm, and fewer capsids were evident in the nucleus. The relative amounts of the different capsid types were quantified by velocity sedimentation in sucrose gradients. The mutant proved to generate 2-fold fewer B-capsids and 10-fold fewer C-capsids (Fig. 4B and C), whereas the amount of A-capsids appeared to be normal (Fig. 4A). The reduction in DNA-containing C-capsids without a concomitant increase in empty A-capsids, which are believed to arise from aborted DNA encapsidation events (reviewed in reference 7), in ADsubTRS1-infected cells suggests that a failure in the sequence of packaging events occurs before the scaffolding proteins exit the capsid.
We were able to further localize the defect by examining the cleavage of concatemeric viral DNA in mutant virus-infected cells, and cleavage occurred normally (Fig. 5). This further localized a defect to a point after DNA cleavage but before the exit of scaffolding proteins from the capsid.
Nuclear organization was also abnormal in ADsubTRS1- compared to ADwt-infected fibroblasts. Large, electron-dense centers of replication and assembly were evident in the nuclei of cells infected with the wild-type virus, but not the mutant (Fig. 3), and FISH analysis demonstrated that mutant DNA is compartmentalized differently than wild-type DNA in the nucleus (Fig. 6). Whereas the fluorescent signal for ADwt DNA coalesces to form one or two large domains late after infection, numerous individual fluorescent puncta of ADsubTRS1 DNA accumulate but do not coalesce. It is possible that pTRS1 functions to properly locate the viral DNA in the nucleus so that it can be efficiently packaged. Alternatively, the altered localization might result from a failure to efficiently package viral DNA.
We favor the view that pTRS1 is needed to produce a normal B-capsid that is competent to accept DNA, i.e., in the absence of pTRS1, only a portion of the B-capsids are competent for DNA packaging. This could explain the simultaneous 2-fold reduction in B-capsids and 10-fold reduction in C-capsids. B-capsids are complex structures. HCMV B-capsids were characterized some years ago to contain a major capsid protein, a minor capsid protein, the smallest capsid protein, and assembly protein (14), along with the minor capsid protein-binding protein (8). More recent work with HSV-1 has shown that its B-capsids include nine virus-coded polypeptides (reviewed in reference 21). Although pTRS1 is not homologous to any of these nine HSV-1 proteins, it is possible that pTRS1 functions as an additional constituent of HCMV B-capsids, and this would be consistent with its presence in virions (32). Further characterization of the B-capsids is needed to reveal whether pTRS1 associates with the particles produced in ADwt-infected cells and whether the B-capsids produced in ADsubTRS1-infected cells exhibit additional abnormalities in their composition.
Although pTRS1 doesn't exhibit homology to the HSV-1 UL25 protein, there are similarities in the phenotypes of ADsubTRS1 and HSV-1 mutants lacking the UL25 gene. The UL25 protein is found in virions (2), and it is required for the encapsidation of HSV-1 DNA but not for the cleavage of concatemers (21). Recent work has shown that the UL25 protein binds to the B-capsid, as well as to viral DNA (27).
Recently, Child et al. (5) have shown that pIRS1 and pTRS1 both complement a vaccinia virus mutant that lacks the E3L double-stranded RNA-binding protein. The complementation experiment argues that the HCMV proteins, like the E3L protein, block the shutoff of translation by host cell antiviral pathways. It is unlikely that this intriguing function is related to the assembly function that we have described for pTRS1. Since both pIRS1 and pTRS1 antagonize the host antiviral response, this function almost certainly resides in their common N-terminal domains. An assembly defect is evident only after infection with a pTRS1-deficient virus and not in the absence of pIRS1. Consequently, the pTRS1 assembly function must reside at least in part in its unique C-terminal domain.
This study was supported by a grant from the National Cancer Institute (CA85786) to T.S. and a fellowship award from the Leukemia and Lymphoma Society to J.E.A.
Present address: Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»